NCT07869264 · NOT YET RECRUITING
An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
This is an observational study, not a test of a new treatment. Researchers in Taiwan will track people with Alzheimer's who are already prescribed LEQEMBI by their doctors. They will record side effects, especially brain swelling and bleeding on scans, plus how the disease progresses. No phase is specified, and no one is assigned a drug.
You may qualify if
- Participants with Alzheimer's Disease who are prescribed LEQEMBI in Taiwan.
- Participants who have been prescribed LEQEMBI and who consent to enroll in the program.
You're excluded if
- None
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-09